Combretastatin A4

For research use only.

Catalog No.S7783

3 publications

Combretastatin A4 Chemical Structure

CAS No. 117048-59-6

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
EUR 95 In stock
EUR 390 In stock
EUR 979 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Combretastatin A4 has been cited by 3 publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 M1\xVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnLOR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gV2tOTUxvNTDt[Yxidm:vYTDj[YxtKGyrbnXzMEBGTDVyPUOuNFBGNTB6IN88US=> NELBNZEyQDd3M{Ww
A-549 NWXLW5hJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXTDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDBMVU1QSCudX7nJINiemOrbn;tZUBk\WyuIHzpcoV{NCCHREWwQVEvOjCHLUC2JO69VQ>? M4S4ZVE5PzV|NUC=
MCF-7 M1HQTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1rmdGN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1ETi15IHLy[YF{fCClYYLjbY5wdWFiY3XscEBtcW6nczygSWQ2OD1|LkiwSU0xPiEQvF2= NULzSXJYOTh5NUO1NC=>
HT-29 M2Pre2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHvxO|JEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBJXC1{OTDjc4xwdiCjZHXuc4NiemOrbn;tZUBk\WyuIHzpcoV{NCCHREWwQVEvOjCHLUC2JO69VQ>? M{HSNFE5PzV|NUC=
MLM melanoma cell NWnVOI5ZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1\sSGN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1NVSCvZXzhco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwNEDFMVA3KM7:TR?= M1mxfFE5PzV|NUC=
M14 NEP2b|BEgXSxdH;4bYNqfHliYYPzZZk> NWHVNZdEUW5idnn0do8h[3m2b4TvfIlkKGGldHn2bZR6KHejczD0[ZN1\WRiYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk[W6lZYKgLG0yPCliY3XscEBtcW6nLDDHTVUxRTBwMECwNUDPxE1? NH7mN4UyOjd{OU[0NC=>
SK-OV3 M4\ud2N6fG:2b4jpZ4l1gSCjc4PhfS=> NFPLU4pKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhfGW|dHXkJIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYX7j[ZIhMFONLV;WN{kh[2WubDDsbY5mNCCJSUWwQVAvODByMTFOwG0> NUC3cGxZOTJ5Mkm2OFA>
HL60 cells NX3FN2ZkS3m2b4TvfIlkcXS7IHHzd4F6 M4H3NVczKGh? Mkn4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAxOSEQvF2= M{i5NlIxPzNzM{W1
SK-OV-3 MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{fvT|Q5KGh? NHLnelVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFAyOyEQvF2= M{nSVVE5PzJ{MUK3
HepG2 cells MYLDfZRwfG:6aXPpeJkh[XO|YYm= MojNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMtKEmFNUC9NE4xODBzNDFOwG0> MknpNVcyOjdyNkG=
ZR-75-1 MYTDfZRwfG:6aXPpeJkh[XO|YYm= MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBbWi15NT2xJINmdGxibHnu[UwhUUN3ME2wMlAxODJ2IN88US=> MUCxO|I1QTZ2OR?=
HeLa cell NH\KbpdEgXSxdH;4bYNqfHliYYPzZZk> M2XsOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEinTHGgZ4VtdCCuaX7lMEBKSzVyPUCuNFAxOyEQvF2= MnH1NVczPDl4NEm=
HCT116 cell NFTVS5VEgXSxdH;4bYNqfHliYYPzZZk> M3uyR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiFVEGxOkBk\WyuIHzpcoUtKEmFNUC9NE4xODB|NTFOwG0> NWTlNmVuOTd{NEm2OFk>
KBV1 cells M3zQd2N6fG:2b4jpZ4l1gSCjc4PhfS=> NH\qd4E4OiCq NVfpS3Y2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hfmmwYnzhd5RqdmVvcnXzbZN1[W62IFvCWlEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNFQh|ryP M3G2VlIxPzNzM{W1
SKOV3 M2rNUGN6fG:2b4jpZ4l1gSCjc4PhfS=> MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC0NkDPxE1? NWi2TnRzOjRyMU[wNFI>
SKOV3 cells Ml[4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHj0b21Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUU0:YMzDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwQVAvODByNEKg{txO M1;3bFI{Pzd{M{C5
HeLa cells MnvnR5l1d3SxeHnjbZR6KGG|c3H5 M3XqemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVEh|ryP NXnsdoE6OTl6N{m3OVg>
DU145 cells MVzDfZRwfG:6aXPpeJkh[XO|YYm= Mn\mR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwOVQh|ryP MVqyOFAyPjByMh?=
DU145 cells MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3nlZmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9NE4xODB3NDFOwG0> MmjFNlM4PzJ|MEm=
SK-N-BE NULhS5VPWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVTCXHFMPzJiaB?= M3\PdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJHNMNU5vQlWgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMEW4JO69VQ>? M{DjWFIzOzJ7NU[x
NCIH460 cells MVfDfZRwfG:6aXPpeJkh[XO|YYm= M1;jclQ5KGh? MkjlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKUDR4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODByNjFOwG0> MkXiNVg{ODN6NEm=
KB-VIN10 cells MUfQdo9tcW[ncnH0bY9vKGG|c3H5 MUK3NkBp NEfmZ5RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCMXZKVjFyIHPlcIx{KG:4ZYKt[ZhxemW|c3nu[{BRNWeyIEG3NE9OTFJzIHHmeIVzKDd{IHjyd{BjgSCvZYTofYxmdmViYnz1[UBie3OjeTygTWM2OD1yLkCwNFch|ryP M4Lu[FIyPjRzN{Cw
HCT116 cells NYTIUml4S3m2b4TvfIlkcXS7IHHzd4F6 MWC3NkBp NHzXR4NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKFt|SG30bJlucWSrbnWgbY5kd3Kyb4LheIlwdiCjZoTldkA4OiCqcoOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OD1yLkCwNFc1KM7:TR?= M3m2XlIyQTV3NEW0
DU145 cells MmnCR5l1d3SxeHnjbZR6KGG|c3H5 Mk\6OFghcA>? NU\zSIJIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMEig{txO MoXQNVg{ODN6NEm=
RS4:11 cells MmfEVJJwdGmoZYLheIlwdiCjc4PhfS=> MnX5O|IhcA>? NHzENFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLTOFoyOSClZXzsd{Bi\nSncjC3NkBpenNiYomgLFMuMDRuNT3kbY1mfGi7bITobYF7d2xvMj35cEkuOix3LXTpdIhmdnmudHX0doF7d2yrdX2gZpJwdWmmZTD0[ZN1NCCLQ{WwQVAvODByODFOwG0> MkjkNlU4QDV4MEW=
HCT 116 NFX5VVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2nsOGNwdmOnboTyZZRqd25id3jpZ4gheHKxZIXj[ZMhPTBnIHnubIljcXSrb36gc4Yh\3Kxd4ToJI9nKGi3bXHuJINwdG:wIIT1cY9zKEiFVDCxNVYtKEmFNUC9NE4xODB7IN88US=> MXixNVcyPDZzMx?=
HeLa cells NXHE[olNS3m2b4TvfIlkcXS7IHHzd4F6 M{nxPFczKGh? M1:3WmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJJme2G8dYLpckBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTB;MD6wNFA6KM7:TR?= MXiyOFY3QTh6OB?=
BNL 1ME A.7R.1 cells NWXCSmRWS3m2b4TvfIlkcXS7IHHzd4F6 NFnBRlVEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDVkxiMV3FJGEvP1JwMTDj[YxteyxiSVO1NF0xNjByMEmg{txO M{G3XFI2Pzh3NkC1
Calu6 M3\JWnBzd2yrZnXyZZRqd25iYYPzZZk> MWC0PEBp Mn3rRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFYXz1OkBi\nSncjC0PEBpenNiYomgd5Bm[3S{b4Doc5RwdWW2comsJGlEPTB;MD6wNFA6PCEQvF2= MlLRNlE4PzR2OUm=
melanoma B16 cell M1nzV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH;oVXBEd26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCvdYLpcoUhdWWuYX7vcYEhSjF4IHPlcIwhdGmwZTygTWM2OD1yLkCwNUDPxE1? M2n6S|EyPzF2NkGz
DU145 cells MYLDfZRwfG:6aXPpeJkh[XO|YYm= NFXYcJpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP NVr5VnJYOjB2OU[5NlM>
HCT116 cells M{PXfnBzd2yrZnXyZZRqd25iYYPzZZk> NGD0fos4OiCq MmSxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNUDPxE1? NV\1N25XOjFzMUKxN|A>
HCT15 cells MUDQdo9tcW[ncnH0bY9vKGG|c3H5 MlG3O|IhcA>? MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEG1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEGg{txO MUOyNVEyOjF|MB?=
HL60 cells M1PPbHBzd2yrZnXyZZRqd25iYYPzZZk> MWS3NkBp M2HPN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M2L4O|IyPjZ|M{G5
A10 cells NXr1VpJVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnGyOFghcA>? MlvKS5Jwf3SqIHnubIljcXSrb36gc4YhemG2IFGxNEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MXKyNlA1PDF4NB?=
HUVEC cells MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUXjWFlMPDhiaB?= NUjrdXVNT3Kxd4ToJIlvcGmkaYTpc44hd2ZiSGXWSWMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NIC1NGszOjB2NEG2OC=>
HL60 cells MXTDfZRwfG:6aXPpeJkh[XO|YYm= M{e1U|czKGh? NEiwNlNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN M4PzVlIzOTN4M{Gy
HL60 cells MlK5VJJwdGmoZYLheIlwdiCjc4PhfS=> MVy3NkBp MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NI\ldnYzOjV5OEGxNS=>
NCI-H522 cells MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYO0PEBp NVnwXFAyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? MoHhNlI6QDJzMkK=
MDA-MB-435 cells NETOPINIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mme5OFghcA>? M1nxN2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? NHvGRXUzOjl6MkGyNi=>
OVCAR3 NYL6WI9PT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWG0PEBp NF\iW|JIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBQXkODUkOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> MUSyNlk5OjF{Mh?=
NCI/ADR-RES cells M3vn[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4\oSlQ5KGh? NVTEd|h2T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLL1HEVk1TTVNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= M2Xa[VIzQTh{MUKy
PC3 cells NFP5NpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{HCbVQ5KGh? NYDhSVVNT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN NVy3TmZCOjJ7OEKxNlI>
DU145 cells MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmX1OFghcA>? NFW0Rm1Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFXTF2NTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> MYSyNlk5OjF{Mh?=
MDA-MB-231 cells M4K5[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MorIOFghcA>? M4jVNmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? M{Kz[FIzQTh{MUKy
CEM cells M3XI[mN6fG:2b4jpZ4l1gSCjc4PhfS=> NH30S3c4OiCq NV;IT|B5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0WPIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MUeyNlY4PjJ2Nx?=
HCT116 cells MonIR5l1d3SxeHnjbZR6KGG|c3H5 M{nMdVczKGh? MnPGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN M3\xPVIzPjd4MkS3
MDA-MB-435 cells NWHyNHgzS3m2b4TvfIlkcXS7IHHzd4F6 NIL2U5M4OiCq MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MmjPNlI3PzZ{NEe=
HaCaT cells M3fmdnBzd2yrZnXyZZRqd25iYYPzZZk> NXjhPGJGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIZWNiXCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NIXUPGszOzB4M{SwNS=>
HL60 cells M1PRb3Bzd2yrZnXyZZRqd25iYYPzZZk> MU[3NkBp NXfWVm1MSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MXeyN|EyPzF5MR?=
HL60 cells MYfQdo9tcW[ncnH0bY9vKGG|c3H5 NWnJendwPzJiaB?= NVXacWtVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTCoN{0pPCx3LXTpcYV1cHmudHjpZZpwdC1{LYnsLU0zNDVvZHnwbIVvgWy2ZYTyZZpwdGm3bTDido9ucWSnIITld5QtKEmFNUC9NE4xODFizszN MojWNlU4QDV4MEW=
HT-29 M{X0O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MorkS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NEXne3YzPTZ6OUGxNS=>
HL60 cells NIDwWZFRem:uaX\ldoF1cW:wIHHzd4F6 MVi3NkBp NUnoflk5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NVqyfY91OjB2MkC0N|k>
Hs578T cells NFzqZlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH3ZVZU1QCCq NWXQ[FBxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUHN3N{jUJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO M{\ueVIzQTh{MUKy
HL60 cells M1O4PWN6fG:2b4jpZ4l1gSCjc4PhfS=> MoTOO|IhcA>? MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NHfoS5IzOzR2NUS5Oi=>
SKOV3 cells MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml\XS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tQXjNiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? M3WyVFI2Pjh7MUGx
MDA-MB-468 cells Ml\DR5l1d3SxeHnjbZR6KGG|c3H5 NIP3TZU1KGSjeYO= M3zKWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNDDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNVEh|ryP NWfJT4FlOjR{MUC1NFM>
MCF7 cells MmLsVJJwdGmoZYLheIlwdiCjc4PhfS=> MlTwO|IhcA>? MoLpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyOTFizszN NELybFQzOjN{OUW2NS=>
H460 MlWzR5l1d3SxeHnjbZR6KGG|c3H5 NHXDWo1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJidHXzeEwhUUN3ME2wMlAxOTJizszN NILWPWgyQDd6M{KwOy=>
H460 MXnQdo9tcW[ncnH0bY9vKGG|c3H5 MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEh2NkCgZ4VtdHNuIFnDOVA:OC5yMEGyOEDPxE1? NX71T4xkOTZ5MkK2N|M>
NCI-H460 cells NHzvRm5EgXSxdH;4bYNqfHliYYPzZZk> MWG3NkBp MnvFR5l1d3SxeHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg1PjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgeIV{fCxiSVO1NF0xNjByMUOg{txO NFezUIYyQDN7Nki1Oy=>
OVCAR8 cells NUK5SZM3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWG5OkBp M3\oOGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUODDj[YxteyCxdnXy[ZhxemW|c3nu[{BRNWeueXPvdJJwfGWrbjDh[pRmeiB7NjDodpMtKEmFNUC9NE4xODF|IN88US=> NIHnW2MzOjB2NEG2OC=>
NCI/ADR-RES cells NY\I[YlSS3m2b4TvfIlkcXS7IHHzd4F6 MnroR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[nlidIL5dIFvKGKudXWg[ZhkdHW|aX;uJIF{e2G7LDDJR|UxRTBwMECxN{DPxE1? M4jOeFI{OjF2NEWy
OVCAR8 cells M13VWWN6fG:2b4jpZ4l1gSCjc4PhfS=> NUDSeGFxQTZiaB?= M2HzOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUODDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB7NjDodpMh[nliR3nlcZNiKHO2YXnubY5oNWKjc3XkJIxq\2i2IH3pZ5Jwe2OxcImsJGlEPTB;MD6wNFE{KM7:TR?= MXiyOVAzPTl7MR?=
NCI/ADR-RES cells M{D0bGN6fG:2b4jpZ4l1gSCjc4PhfS=> MnT5PVYhcA>? NEPNNGpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA6PiCqcoOgZpkhT2mnbYPhJJN1[WmwaX7nMYJie2WmIHzp[4h1KG2rY4Lvd4NweHluIFnDOVA:OC5yMEGzJO69VQ>? NXvL[FBsOjVyMkW5PVE>
OVCAR8 cells NGmwZnJEgXSxdH;4bYNqfHliYYPzZZk> MnXWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHL5JJRzgXCjbjDicJVmKGW6Y3z1d4lwdiCjc4PhfUwhUUN3ME2wMlAxOTNizszN NF62VXUzOzJzNES1Ni=>
HuTu 80 cells M4LqenBzd2yrZnXyZZRqd25iYYPzZZk> NIDvdIg4OiCq NIHkSWJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBJfVS3IEiwJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGzO{DPxE1? NH34XHczOjN{OUW2NS=>
K562 cells M2jtSGN6fG:2b4jpZ4l1gSCjc4PhfS=> NWrjT4F2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyxiSVO1NF0xNjByMUSg{txO MnnPNVk5Ozd3OUS=
NCI/ADR (MDR) cells MWnGeY5kfGmxbjDhd5NigQ>? NIDsXHJE\WyuIHP5Z4xmKGG{cnXzeEBqdiCQQ1mvRWRTKCiPRGKpJINmdGy|IHL5JIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlMEBKSzVyPUCuNFAyPSEQvF2= MWOxOlM4PzF6Nx?=
HUVEC MWXQdo9tcW[ncnH0bY9vKGG|c3H5 Mo\LRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVW\FR{whUUN3ME2wMlAxOTVizszN MlX3NVY4OjJ4M{O=
KB cell MXPQdo9tcW[ncnH0bY9vKGG|c3H5 M1HpW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KgZ4VtdCCuaX7lJIJ6KG2ndHj5cIVv\SCkbIXlJIR6\SCjc4PhfUwhUUN3ME2wMlAxOTVizszN MoXoNVcxOzRzNEe=
KB-VIN10 cell MkPyVJJwdGmoZYLheIlwdiCjc4PhfS=> M1Pub2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KtWmlPOTBiY3XscEBtcW6nIHL5JI1mfGi7bHXu[UBjdHWnIHT5[UBie3OjeTygTWM2OD1yLkCwNVUh|ryP M17tUFE4ODN2MUS3
Human SH-SY5Y neuroblastoma cells NUPUcY97TnWwY4Tpc44h[XO|YYm= NUnMTlltUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgTJVu[W5iU1itV3k2YSCwZYXyc4Jt[XO2b33hJINmdGy|LDDJR|UxRTBwMECxOUDPxE1? M2TsO|E2QTZ|N{Ky
SW620 cells NWewbolwWHKxbHnm[ZJifGmxbjDhd5NigQ>? MW[3NkBp MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDTW|YzOCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyPTJizszN M4HpV|IzOzJ7NU[x
Molt4/C8 cells NX30PJY{WHKxbHnm[ZJifGmxbjDhd5NigQ>? NEHmVFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3vcJQ1N0N6IHPlcIx{NCCLQ{WwQVAvODBzNjFOwG0> MV6xO|A{PDF3MB?=
ACHN cell MWPQdo9tcW[ncnH0bY9vKGG|c3H5 Mlm0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDkdpVoKHKnc3nzeIFvfCCDQ1jOJINmdGxibHnu[UBmgHC{ZYPzbY5oKE2GUkGgZpkhSWyjbXHyJGJtfWViYYPzZZktKEmFNUC9NE4xODF4IN88US=> NVXOZ|Y2OTd{OE[zPVM>
Molt4/C8 cells M3nldXBzd2yrZnXyZZRqd25iYYPzZZk> NUfmR3F1OyCmYYnz NHnBN4xCdnSrcILvcIln\XKjdHn2[UBm\m[nY4SgZYdicW6|dDDoeY1idiCPb3z0OE9EQCClZXzsd{Bi\nSncjCzJIRigXNuIFnDOVA:OC5yMEG2JO69VQ>? NHOzelkyPzRzOU[wOy=>

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
- Collapse

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
- Collapse
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A
Smiles COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID